ISU Abxis Co., Ltd.
KKRX:0868903,550.00
KRW
-75.00
(-2.07%)
ISIN
KR7086890001
Return %
Stock
S&P 500
1Y
-29.84
13.14
3Y
-36.72
80.78
5Y
-66.98
67.74
Capital Structure
KRW
•
in mil. unless spec.Working Capital
KRW
•
in mil. unless spec.Growth Rates
KRW
•
in mil. unless spec.Quarterly Revenue
KRW
•
in mil. unless spec.Quarterly Earnings Per Share
KRW
•
in mil. unless spec.Quarterly Dividends Per Share
KRW
•
in mil. unless spec.Company Description
- CEO
- Yup Hwang
- Full Time Employees
- 190
- Sector
- Health technology
- Industry
- Pharmaceuticals: major
- Address
- Seongnam-si South Korea
- IPO Date
- Feb 3, 2009
- Website
- abxis.com
- Similar Companies
- Business
- ISU Abxis Co., Ltd. is a South Korea-based biopharmaceutical company that specializes in the research, development, manufacturing, and commercialization of antibody therapeutics, biosimilars, and orphan drugs for rare and intractable diseases. Founded in March 2001 as Petagen Co., Ltd. and renamed to ISU Abxis Co., Ltd. in November 2004, the company is headquartered in Seongnam-si, Gyeonggi-do, South Korea, and operates as a biotechnology affiliate of ISU Group. The company operates primarily within the biopharmaceuticals and biotechnology sector, focusing on recombinant protein engineering, monoclonal antibodies, and contract development and manufacturing organization (CDMO) services. Its commercialized product portfolio comprises Clotinab (abciximab), an anti-thrombotic platelet aggregation inhibitor utilized during percutaneous coronary intervention; Abcertin (imiglucerase), a recombinant enzyme replacement therapy indicated for Type 1 Gaucher disease; and Fabagal (agalsidase beta), a recombinant enzyme replacement therapy designed for Fabry disease. Alongside its commercial treatments, ISU Abxis provides biopharmaceutical CDMO solutions, offering cell line development, process development, analytical testing, and cGMP-compliant biomanufacturing for biopharmaceutical developers. The company's advanced research and development pipeline includes ISU104 (barecetamab), a novel human monoclonal antibody targeting ErbB3 for solid tumors and head and neck squamous cell carcinoma, with further extensions into antibody-drug conjugates (ADCs) and CAR-NK cell therapies; ISU305, an eculizumab biosimilar for paroxysmal nocturnal hemoglobinuria; ISU304 (dalcinonacog alfa), a recombinant Factor IX candidate for hemophilia B; and ISU203, a preclinical anti-acid sphingomyelinase (anti-ASM) antibody for neuroinflammatory conditions and Alzheimer's disease. ISU Abxis serves hospitals, medical institutions, and specialized healthcare providers globally, with commercial and distribution channels extending across South Korea, the Middle East and North Africa (MENA), Eurasia, Latin America, and the Asia-Pacific region. In recent developments, the company has expanded its oncology and rare disease initiatives through strategic licensing agreements and market expansions. ISU Abxis executed a license and development agreement with Actinium Pharmaceuticals to provide proprietary antibody technology for the ATNM-400 therapeutic candidate, securing milestone and royalty rights. Concurrently, the company has broadened its global market reach by commercializing Abcertin across the MENA region and sustaining international supply and tech-transfer collaborations for Fabagal and ISU305 across Eurasia and emerging markets, while advancing novel oncology platforms in antibody-drug conjugates.